We quantified p16 expression by immunohistochemistry in 100 gliomas with diverse histological features and grades, for which CDKN2A status was determined using highly sensitive, targeted DNA-based hybridization capture next-generation sequencing technology. The gene discussed is CDKN2A; the disease is central nervous system cancer.